Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE An understanding of the intrinsic and acquired mechanism of MET resistance will be fundamental for the development of new therapeutic interventions.<b>Areas covered</b>: This article provides a systematic review of phase II randomized and phase III clinical trials investigating the use of MET inhibitors in the treatment of cancer. 31783719

2020

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE STMN1 upregulation mediates HCC and hepatic stellate cells crosstalk to aggravate cancer through triggering MET pathway. 31785057

2020

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Using human cancer cell lines, including Hs746T (<i>MET</i>-mutated/amplified), H596 (<i>MET</i>-mutated), and H1993 (<i>MET</i>-amplified) cells, as well as BEAS-2B bronchial epithelial cells, we investigated whether MET is involved in the regulation of immune checkpoint pathways. 31480591

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE MET tyrosine kinase receptor [MET, c-MET, hepatocyte growth factor (HGF) receptor] pathway activation is associated with the appearance of several hallmarks of cancer. 31512514

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Here we provide an overview of the mechanism of action and rationale of c-MET inhibition in cancer, the efficacy of approved agents, and novel promising c-MET-inhibitors and novel targeted combination strategies under development in different cancer types, with a focus on the safety profile and tolerability of these compounds. 30649748

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 AlteredExpression BEFREE We then identified the pyruvate dehydrogenase complex (PDHC) and GLS/GLS1 as crucial substrates of HGF-activated MET kinase; MET-mediated phosphorylation inhibits PDHC activity but activates GLS to promote cancer cell metabolism and biogenesis. 30786811

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE In particular, MET targets cancer stem cells (CSCs) in a variety of cancer types but these compounds have not been extensively tested for combination therapy. 30918522

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE The oncogene MET into exosomes was identified from icotinib-resistant lung cancer cells, and this was also presented in exosomes in NSCLC patients diagnosed with cancer metastasis after icotinib treatment. 31606039

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 AlteredExpression BEFREE Mesenchymal epithelial transition (C-MET) factor overexpression has been found in many types of cancer and has served as an important molecular target for therapeutic intervention. 31729060

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Small molecule inhibitors or bispecific antibodies that can target both EGFR and cMET are therefore emerging as novel options for cancer therapy. 31584260

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. 30674502

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE These results highlighted the roles of AXL/MET in cancer growth and metastasis and further verified that the critical targets of DCC-2036 are AXL and MET, especially AXL. 30289981

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Systematic analysis of NLMP suggests nuclear localization of RTK/MET kinases resemble cancer cell clearance. 30700325

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Removal of MET by sustained treatment of antibodies blocked cancer cell migration and invasion. 30760737

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Activation of the MET/FAK axis is known to arise through cancer extrinsic and intrinsic cues. 31296956

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Of the 34 metastatic patients who never received a MET inhibitor, the mOS was 8.1 months; those in this group with concurrent MET amplification had a trend toward worse survival compared to cancers without MET amplification (5.2 months vs 10.5 months, P =  0.06). 31200835

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE On the contrary, MET deregulation is associated with tumorigenesis in many kinds of cancer. 30670153

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE SHR-A1403 showed high affinity to c-Met proteins derived from human or monkey and potent inhibitory effects in cancer cell lines with high c-Met protein expression. 30643210

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE [<sup>11</sup>C]methionine ([<sup>11</sup>C]Met) was used for cancer imaging based on upregulated amino acid transport and protein synthesis in different tumor types. 31119488

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE As a consequence, anti-MET VHH pool dramatically suppresses cancer cell proliferation, viability, and colony formation <i>in vitro</i>, and inhibits tumorigenesis and growth in mice. 30361332

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase. 30550851

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Collectively, differential intrapatient and interpatient expression of HER2, EGFR, and MET may determine clinical response to HER kinase inhibitors in <i>ERBB2</i>-amplified EG cancer. 30463996

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Given the close connection between oncogenic signaling and EMT repressors, the EMT has emerged as a therapeutic target or goal (in terms of MET reversion) in cancer therapy. 30649699

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE [<sup>11</sup>C]-MET is superior to [<sup>18</sup>C]-fluorodeoxyglucose (FDG) for PET imaging, suggesting that MET overuse in cancer ("Hoffman effect") is greater than glucose overuse in cancer ("Warburg effect"). 30725423

2019

Entrez Id: 4233
Gene Symbol: MET
MET
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 AlteredExpression BEFREE Hepatocyte growth factor receptor (c-MET) is a receptor tyrosine kinase overexpressed in malignant cancer types, including breast cancer. 30962283

2019